Evidence map›Paper›PMID 42777006›Full record

ArticlePLoS neglected tropical diseases2026

A multiplex serological assay for quantification of arbovirus antibody kinetics and neutralizing antibodies.

Laura Garcia, Victor Yman, Marie-Fabrice Gasasira, Françoise Donnadieu, Jason Rosado, Lucie Cappuccio, Damien Hoinard, Philippe Desprès, Stéphane Petres, Jean-Claude Manuguerra and 14 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Laura GarciaInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.ORCID https://orcid.org/0000-0001-8044-5365
Victor YmanInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.
Marie-Fabrice GasasiraInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.
Françoise DonnadieuInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.
Jason RosadoInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.
Lucie CappuccioEnvironment and Infectious Risks Unit, Institut Pasteur, Paris, France.
Damien HoinardEnvironment and Infectious Risks Unit, Institut Pasteur, Paris, France.
Philippe DesprèsProcessus Infectieux en Milieu Insulaire Tropical (PIMIT), Université de La Réunion, INSERM U1187, CNRS 9192, IRD 249, Plateforme Technologique CYROI, Sainte-Clotilde, La Réunion, France.
Stéphane PetresInstitut Pasteur, Université Paris Cité, Production and Purification of recombinant Proteins Platform, CNRS UMR3528, Paris, France.
Jean-Claude ManuguerraEnvironment and Infectious Risks Unit, Institut Pasteur, Paris, France.
In-Kyu YoonInternational Vaccine Institute, Seoul, Republic of Korea.
Taweewan HunsawongDepartment of Virology, Walter Reed Army Institute of Research-Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
Maria Theresa P AleraPhilippines-AFRIMS Virology Research Unit, Cebu City, Philippines.
Emily S GurleyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Nikos VasilakisDepartment of Pathology and Center for Vector-Borne and Zoonotic Diseases, University of Texas, Medical Branch, Galveston, Texas, United States of America.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Ziaur RahmanInternational Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b), Dhaka, Bangladesh.
Ilaria DorigattiMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
Chris DrakeleyDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Inès Vigan-WomasInstitut Pasteur de Dakar, Dakar, Senegal.
Makhtar NiangInstitut Pasteur de Dakar, Dakar, Senegal.
Henrik SaljeDepartment of Genetics, University of Cambridge, Cambridge, United Kingdom.
Jessica VanhomwegenEnvironment and Infectious Risks Unit, Institut Pasteur, Paris, France.
Michael WhiteInfectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, INSERM U1347, Paris, France.ORCID https://orcid.org/0000-0002-7472-4138

Funding

Wellcome Trust
6 · The paper itself

Abstract

Arboviruses such as dengue virus (DENV) and chikungunya virus (CHIKV) pose major global health threats. To support serological surveillance and study cross-reactivity, an in-house multiplex bead-based immunoassay was developed to measure IgG responses against a wide panel of orthoflavivirus and alphavirus antigens. Samples from Senegal, France, the Philippines, and Bangladesh enabled analyses to be carried out in endemic and non-endemic regions. IgG kinetics following DENV1 and CHIKV infections revealed virus-specific temporal profiles and identified antigens, such as CHIKV E2 and VLP, as well as DENV1 EDIII and SNAP-tagged EDIII, as promising markers for serosurveillance. A two-step Random Forest model was used to classify PRNT-positive samples and predict PRNT titers. CHIKV showed a strong correlation between IgG and PRNT titers (R² = 0.71), while DENV1 showed weaker performance (R² = 0.42). These results support the use of multiplex serology for arbovirus surveillance and highlight the limitations of using binding antibodies to predict neutralisation, particularly for orthoflaviviruses.

Indexed as

Antibodies, NeutralizingAntibodies, ViralArbovirusesBangladeshDengueDengue VirusHumansImmunoassayImmunoglobulin GPhilippinesSenegalSerologic TestsAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Identifiers

PMID42777006
PMCPMC13626472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.